Beacon Therapeutics’ gene therapy for X-linked retinitis pigmentosa continued to advance after meeting its FDA-endorsed primary endpoint in a pivotal Phase 2/3 trial. The company reported that laruparetigene zovaparvovec improved low-luminance visual acuity, with a meaningful fraction of patients in both high- and low-dose groups achieving prespecified letter gains versus an untreated control. The Phase 3/VISTA readout increases the probability of near-term regulatory engagement in a market where gene therapy launches have been mixed and where payer and manufacturing expectations will be closely watched. Beacon also signaled it is preparing a BLA after the pivotal success. In parallel, a separate report reiterated the same Phase 3 trajectory, reinforcing that XLRP remains one of the clearest clinical pathways to approval in inherited ocular disease.